Quality-by-design approach as a systematic tool for the development of nanopharmaceutical products.

Clicks: 195
ID: 66437
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
In recent decades, extensive emphasis has been given on developing nanopharmaceutical products for improving the therapeutic performance of drugs, resulting in an increasing number of product approvals by drug regulatory agencies. Although nanopharmaceuticals are subjected to the same regulatory pathways as conventional pharmaceutical products, their biopharmaceutical characteristics at the nanoscale make them vulnerable to high variability in quality. Positive effects on drug quality assurance have resulted from adopting systematic quality-by-design (QbD) principles, boosting pharmaceutical manufacturing with improvements in the quality, safety, and efficacy of drugs.
Reference Key
beg2019qualitybydesigndrug Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Beg, Sarwar;Rahman, Mahfoozur;Kohli, Kanchan;
Journal Drug discovery today
Year 2019
DOI S1359-6446(18)30361-1
URL
Keywords
doe hplc-uv/pad analysis mase marrubium vulgare l. leave extract copper(ii)-induced stress

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.